Scynexis Stock News

Gainers Casper Sleep Inc. (NYSE: CSPR ) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The company also reported Q3 earnings results. Creative Realities, Inc. (NASDAQ: CREX ) gained 79.5% to settle at $2.62 as the company reported a merger with Reflect Systems on Friday. Patriot National Bancorp, Inc. (NASDAQ: PNBK ) climbed 50.4% to settle at $15.04. Patriot National Bancorp and American Challenger Development Corp. agreed to merge. Trio-Tech International (NYSE: TRT ) jumped 36% to settle at $6.73 after the company reported Q1 results, posting a 49% year-over-year increase in total revenue. SCYNEXIS, Inc. (NASDAQ: SCYX ) rose 25% to close at $6.75. SCYNEXIS, last week, posted a Q3 net loss of C$1.252 million. Matterport, Inc. (NASDAQ: MTTR ) gained 22.3% to close at $27.12. Newegg Commerce, Inc. (NASDAQ: NEGG ) surged 21.3% to settle at $19.21. After the closing bell, Newegg Commerces F-1 filing showed registration for a $300 million common stock offering.

Michael Burry Nukes His Portfolio, Exits All Bearish Positions Up until now, "the big short" Michael Burry was best known for periodically and inexplicably nuking his twitter account before promptly restoring it. Now, we can also his investment portfolio to the list of things the famous subprime shorter tends to nuke every now and then. As a reminder, two quarters ago Burry''s 13F caused a stir across trading desks when the "Big Short" revealed a major Tesla put, which with nominal value of $534 million and representing just over 800K underlying shares, was Burry''s largest position in Q1. Also notable was Burry''s aggressive positioning for a surge in inflation (as a reminder, it was Burry back in February warned that Weimar hyperinflation is coming), which as of March 31 he traded as follows: PUT on the TLT 20+ Year TSY bond ETF, equivalent to some 1.266MM shares or $171.5 million CALL on the TBT 20+ Year Treasury Ultrashort ETF, equivalent to 2.536MM shares or $55.1 million CALL on the TTT 20+ Year Treasury Ultrashort ETF, equivalent to 100K shares or $4.6 million CALL on the 3x levered TMV 20Y Treasury Bear ETF, equivalent to 38,400 shares or $3.1 million Outright long in the TBT 20Y Treasury Ultrashort ETF, amounting to 300,000 shares or $6.5 Million.

Burry, who has been warning of an epic stock-market crash, took a knife to his stock portfolio in the third quarter.

SCYNEXIS, Inc. (SCYX) CEO Marco Taglietti on Q3 2021 Results - Earnings Call Transcript

Scynexis (SCYX) delivered earnings and revenue surprises of 92.41% and 3.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

JERSEY CITY, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

JERSEY CITY, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

JERSEY CITY, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infections Subpopulation analysis of 74 patients from ongoing Phase

Analysis of subpopulations from a total of 74 patients evaluated to date from FURI includes outcomes by disease, bone and joint infections, and mouth and throat candidiasis Analysis of subpopulations

Submission is part of the Hansoh Pharma licensing agreement and strategic partnership to research, develop and commercialize ibrexafungerp in the Greater China region Submission is part of the Hansoh

JERSEY CITY, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan

JERSEY CITY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in th

JERSEY CITY, N.J., July 02, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista